Tuesday, December 21, 2010

Covidien plc to Report First-Quarter Results on February 1, 2011


DUBLIN, Monday, December 20th 2010 [ME NewsWire]:

(BUSINESS WIRE)-- Covidien plc (NYSE: COV) will report first-quarter results before trading begins on February 1, 2011. The Company will hold a conference call for investors at 8:30 a.m. ET. The call can be accessed in the following ways:

* At Covidien’s website: http://investor.covidien.com

* By telephone: For both “listen-only” participants and those participants who wish to take part in the question-and-answer portion of the call, the telephone dial-in number in the U.S. is 866-700-7101. For participants outside the U.S., the dial-in number is 617-213-8837. The access code for all callers is 21441069.

* Through an audio replay: A replay of the conference call will be available beginning at 11:30 a.m. on February 1, 2011, and ending at 5:00 p.m. on February 8, 2011. The dial-in number for U.S. participants is 888-286-8010. For participants outside the U.S., the replay dial-in number is 617-801-6888. The replay access code for all callers is 93591283.


ABOUT COVIDIEN

Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2010 revenue of $10.4 billion, Covidien has approximately 42,000 employees worldwide in more than 60 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.


For media enquiries, please contact:
Covidien
Eric Kraus, 508-261-8305
Senior Vice President
Corporate Communications
eric.kraus@covidien.com

Coleman Lannum, CFA
508-452-4343
Vice President
Investor Relations
cole.lannum@covidien.com


Bruce Farmer, 508-452-4372
Vice President
Public Relations
bruce.farmer@covidien.com

No comments:

Post a Comment